© 2015, Sociedade Brasileira de Pneumologia e Tisiologia. All rights reserved. Objective: To assess the direct and indirect costs of diagnosing and treating community-acquired pneumonia (CAP), correlating those costs with CAP severity at diagnosis and identifying the major cost drivers. Methods: This was a prospective cost analysis study using bottom-up costing. Clinical severity and mortality risk were assessed with the pneumonia severity index (PSI) and the mental Confusion-Urea-Respiratory rate-Blood pressure-age ≥ 65 years (CURB-65) scale, respectively. The sample comprised 95 inpatients hospitalized for newly diagnosed CAP. The analysis was run from a societal perspective with a time horizon of one year. Results: Expressed as mean ± st...
Background: Utilization of diagnostics and biomarkers are the second largest cost drivers in the man...
AbstractBackgroundCommunity-acquired pneumonia (CAP) is one of the most common acute infections asso...
Background: Utilization of diagnostics and biomarkers are the second largest cost drivers in the man...
Objective: To assess the direct and indirect costs of diagnosing and treating community-acquired pne...
ABSTRACT: Community-acquired pneumonia (CAP) has a high incidence and involves an important consumpt...
© 2020 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open ac...
BACKGROUND:Community-acquired pneumonia (CAP) is a major cause of mortality and morbidity worldwide....
Background Community-acquired pneumonia (CAP) is a major cause of mortality and morbidity worldwide....
In Turkey, there is inadequate data about the direct or indirect cost of community acquired pneumoni...
In Turkey, there is inadequate data about the direct or indirect cost of community acquired pneumoni...
In Turkey, there is inadequate data about the direct or indirect cost of community acquired pneumoni...
Community-acquired pneumonia (CAP) is an infectious lung inflammation contracted outside the hospita...
Background: Community-acquired pneumonia (CAP) is one of the most common acute infections associated...
Purpose — to study rationality of financial expenses on the treatment of patients with the severe pn...
Background: Utilization of diagnostics and biomarkers are the second largest cost drivers in the man...
Background: Utilization of diagnostics and biomarkers are the second largest cost drivers in the man...
AbstractBackgroundCommunity-acquired pneumonia (CAP) is one of the most common acute infections asso...
Background: Utilization of diagnostics and biomarkers are the second largest cost drivers in the man...
Objective: To assess the direct and indirect costs of diagnosing and treating community-acquired pne...
ABSTRACT: Community-acquired pneumonia (CAP) has a high incidence and involves an important consumpt...
© 2020 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open ac...
BACKGROUND:Community-acquired pneumonia (CAP) is a major cause of mortality and morbidity worldwide....
Background Community-acquired pneumonia (CAP) is a major cause of mortality and morbidity worldwide....
In Turkey, there is inadequate data about the direct or indirect cost of community acquired pneumoni...
In Turkey, there is inadequate data about the direct or indirect cost of community acquired pneumoni...
In Turkey, there is inadequate data about the direct or indirect cost of community acquired pneumoni...
Community-acquired pneumonia (CAP) is an infectious lung inflammation contracted outside the hospita...
Background: Community-acquired pneumonia (CAP) is one of the most common acute infections associated...
Purpose — to study rationality of financial expenses on the treatment of patients with the severe pn...
Background: Utilization of diagnostics and biomarkers are the second largest cost drivers in the man...
Background: Utilization of diagnostics and biomarkers are the second largest cost drivers in the man...
AbstractBackgroundCommunity-acquired pneumonia (CAP) is one of the most common acute infections asso...
Background: Utilization of diagnostics and biomarkers are the second largest cost drivers in the man...